Abstract
The growth and metastatic spread of cancer is directly related to tumor angiogenesis1, and the driving factors need to be understood to exploit this process therapeutically2,3. However, tumor cells and their normal stroma express a multitude of candidate angiogenic factors2, and very few specific inhibitors have been generated to assess which of these gene products are only innocent bystanders and which contribute significantly to tumor angiogenesis4–6 and metastasis6–8. Here we investigated whether the expression in tumors of a secreted fibroblast growth factor (FGF)-binding protein (FGF-BP)9 that mobilizes and activates10 locally stored FGFs (ref. 11) can serve as an angiogenic switch molecule3. Developmental expression of the retinoid-regulated FGf-BP gene12 is prominent in the skin and intestine during the perinatal phase and is down-modulated in the adult13. The gene is, however, upregulated in carcinogen-induced skin tumors13, in squamous cell carcinoma (SCC)10 and in some colon cancer cell lines and tumor samples. To assess the significance of FGF-BP expression in tumors, we depleted human SCC (ME-180) and colon carcinoma (LS174T) cell lines of their endogenous FGF-BP by targeting with specific ribozymes. We found that the reduction of FGF-BP reduced the release of biologically active basic FGF (bFGF) from cells in culture. Furthermore, the growth and angiogenesis of xenograft tumors in mice was decreased in parallel with the reduction of FGF-BP. This suggests that human tumors can utilize FGF-BP as an angiogenic switch molecule.
Similar content being viewed by others
References
Weidner, N. Intratumor microvessel density as a prognostic factor in cancer. Am. J. Pathol. 147, 9–19 (1995).
Liotta, L.A., Steeg, P.S., & Stetler-Stevenson, W.G. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 64, 327–336 (1991).
Hanahan, D. & Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353–364 (1996).
Dvorak, H.F., Brown, L.F., Detmar, M. & Dvorak, A.M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146, 1029–1039 (1995).
Schulte, A.M. et al. Human trophoblast and choriocarcinoma expression of the growth factor pleiotrophin attributable to germ line insertion of an endogenous retrovirus. Proc. Natl. Acad. Sci. USA 93, 14759–14764 (1996).
Czubayko, F., Schulte, A.M., Berchem, G.J. & Wellstein, A. Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin. Proc. Natl. Acad. Sci. USA 93, 14753–14758 (1996).
Asano, M., Yukita, A., Matsumoto, T., Kondo, S. & Suzuki, H. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor 121. Cancer Res. 55, 5296–5301 (1995).
Warren, R.S., Yuan, H., Matli, M.R., Gillett, N.A. & Ferrara, N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Invest. 95, 1789–1797 (1995).
Wu, D., Kan, M., Sato, G.H., Okamoto, T. & Sato, J.D. Characterization and molecular cloning of a putative binding protein for heparin-binding growth factors. J. Biol. Chem. 266, 16778–16785 (1991).
Czubayko, F., Smith, R.V., Chung, H.C. & Wellstein, A. Tumor growth and angiogenesis induced by a secreted binding protein for fibroblast growth factors. J. Biol. Chem, 269, 28243–28248 (1994).
Burgess, W.H. & Maciag, T. The heparin-binding (fibroblast) growth factor family of proteins. Annu. Rev. Biochem. 58, 575–606 (1989).
Liaudet-Coopman, E.D.E. & Wellstein, A. Regulation of gene expression of a binding protein for fibroblast growth factor by retinoic acid. J. Biol. Chem. 271, 21303–21308 (1996).
Kurtz, A., Darwiche, N., Harris, V., Wang, H.L. & Wellstein, A. Expression of a binding protein for FGF is associated with epithelial development and skin carcinogenesis. Oncogene 14, 2671–2681 (1997).
Czubayko, F., Riegel, A.T. & Wellstein, A. Ribozyme-targeting elucidates a direct role of pleiotrophin in tumor growth. J. Biol. Chem. 269, 21358–21363 (1994).
Li, Y.S. et al. Cloning and expression of a developmentally regulated protein that induces mitogenic and neurite outgrowth activity. Science 250, 1690–1694 (1990).
Fang, W.J., Hartmann, N., Chow, D., Riegel, A.T. & Wellstein, A. Pleiotrophin stimulates fibroblasts, endothelial and epithelial cells, and is expressed in human cancer. J. Biol. Chem. 267, 25889–25897 (1992).
Liaudet-Coopman, E.D.E., Berchem, G.J. & Wellstein, A. In vivo inhibition of angiogenesis and induction of apoptosis by retinoic acid in squamous cell carcinoma. Clin. Cancer Res. 3, 179–184 (1997).
Horak, E.R. et al. Angiogenesis, assessed by platelet/endothelial Cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 340, 1120–1124 (1992).
Kuan, S.F., Byrd, J.C., Basbaum, C.B. & Kim, Y.S. Characterization of quantitative mucin variants from a human colon cancer cell line. Cancer Res. 47, 5715–5724 (1987).
Chen, C.J., Banerjea, A.C., Harmison, G.G., Haglund, K. & Schubert, M. Multi-target-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication—potential effectiveness against most presently sequenced HIV-1 isolates. Nucleic Acids Res. 20, 4581–4589 (1992).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Czubayko, F., Liaudet-Coopman, E., Aigner, A. et al. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat Med 3, 1137–1140 (1997). https://doi.org/10.1038/nm1097-1137
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/nm1097-1137
- Springer Nature America, Inc.
This article is cited by
-
Eldecalcitol (ED-71)-induced exosomal miR-6887-5p suppresses squamous cell carcinoma cell growth by targeting heparin-binding protein 17/fibroblast growth factor–binding protein-1 (HBp17/FGFBP-1)
In Vitro Cellular & Developmental Biology - Animal (2020)
-
Fibroblast Growth Factor Binding Protein 3 (FGFBP3) impacts carbohydrate and lipid metabolism
Scientific Reports (2018)
-
Eldecalcitol (ED-71), an analog of 1α,25(OH)2D3, inhibits the growth of squamous cell carcinoma (SCC) cells in vitro and in vivo by down-regulating expression of heparin-binding protein 17/fibroblast growth factor-binding protein-1 (HBp17/FGFBP-1) and FGF-2
In Vitro Cellular & Developmental Biology - Animal (2017)
-
Up-regulation of FGFBP1 signaling contributes to miR-146a-induced angiogenesis in human umbilical vein endothelial cells
Scientific Reports (2016)
-
1α,25(OH)2D3 inhibits FGF-2 release from oral squamous cell carcinoma cells through down-regulation of HBp17/FGFBP-1
In Vitro Cellular & Developmental Biology - Animal (2014)